# reload+after+2024-01-22 20:30:21.501254
address1§8800 Health Science Center Parkway
city§Bryan
state§TX
zip§77807-1107
country§United States
phone§302 355 0650
website§https://www.ibioinc.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.
fullTimeEmployees§26
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Martin B. Brenner D.V.M., Ph.D.', 'age': 52, 'title': 'CEO & Chief Scientific Officer', 'yearBorn': 1971, 'fiscalYear': 2023, 'totalPay': 577311, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Felipe  Duran', 'age': 43, 'title': 'Chief Financial Officer', 'yearBorn': 1980, 'fiscalYear': 2023, 'totalPay': 1072087, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Stephen  Kilmer', 'title': 'Investor Relations Officer', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Marc  Banjak J.D.', 'title': 'General Counsel', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Robert B. Kay', 'age': 83, 'title': 'Interim Secretary & Interim Treasurer', 'yearBorn': 1940, 'fiscalYear': 2023, 'totalPay': 92692, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§10
boardRisk§6
compensationRisk§9
shareHolderRightsRisk§4
overallRisk§8
governanceEpochDate§1704067200
compensationAsOfEpochDate§1703980800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§-3.704
priceToSalesTrailing12Months§51.73002
currency§USD
dateShortInterest§1702598400
forwardEps§-2.4
exchange§ASE
quoteType§EQUITY
shortName§iBio, Inc.
longName§iBio, Inc.
firstTradeDateEpochUtc§1219152600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§f0a2faf7-8166-3ef6-9b69-f7e5c346e13d
gmtOffSetMilliseconds§-18000000
recommendationMean§3.0
recommendationKey§hold
quickRatio§0.071
grossMargins§1.0
ebitdaMargins§0.0
trailingPegRatio§None
